Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
November 21 2022 - 4:05PM
Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage
biopharmaceutical company focused on advancing the next wave of
medicine for allergy and inflammation, today announced that Chief
Executive Officer Natalie Holles will participate in a fireside
chat at the Evercore ISI 5th Annual HealthCONx Conference on
Thursday, November 29, 2022, from 10:05-10:25 a.m. ET.
A live audio webcast will be available within the
Investors and Media section of the Third Harmonic Bio website.
An archived replay will be accessible for 90 days following the
event.
Third Harmonic Bio is a clinical-stage
biopharmaceutical company focused on advancing the next wave of
medicine for allergy and inflammation. Third Harmonic’s lead
product candidate, THB001, is a highly selective, oral
small-molecule inhibitor of KIT, a cell surface receptor that
serves as the master regulator of mast cell function and survival.
THB001 is currently being evaluated in a Phase 1b proof-of-concept
study in chronic inducible urticaria. With promising drug-like
properties and an encouraging early clinical profile, THB001 has
the potential to revolutionize the treatment of a broad range of
dermatologic, respiratory and gastrointestinal allergic and
mast-cell-mediated inflammatory diseases. For more information,
please visit the Third Harmonic Bio website:
www.thirdharmonicbio.com.
Media Contact: Lori Murray
lori.murray@thirdharmonicbio.com
Investor Contact: Bob Ho
rho@thirdharmonicbio.com
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
From Oct 2023 to Oct 2024